Sun Pharma's growth outlook supported by new launches
pre-market1 source ↓written by the desknot a recommendation
Sun Pharmaceutical Industries reported strong growth in its global specialty business for Q2 FY2023, alongside resilient domestic sales. Despite challenges in the US generics segment, new product launches like Unloxcyt and Leqselvi are set to enhance long-term growth prospects. Analysts maintain a 'BUY' rating with an upside of 11-18% from Friday's close of ₹1,692.8.
Not investment advice. For informational purposes only.